Oread

Oread is a biotechnology company focused on developing a new class of tissue-specific medicines for inflammatory and autoimmune skin diseases. The company utilizes a proprietary platform designed for 'skin-restricted' delivery, which aims to maximize local therapeutic efficacy while minimizing systemic exposure and associated side effects. Founded by leading dermatology experts and backed by prominent venture capital, Oread is advancing a pipeline of small molecule inhibitors targeting validated pathways such as Janus kinase (JAK). Its lead programs focus on high-unmet-need conditions including vitiligo, atopic dermatitis, and psoriasis. By combining deep expertise in skin immunology with innovative drug delivery science, the company aims to redefine the standard of care for patients with chronic skin disorders.